Skip to main content
Glama

Xero

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already provide readOnlyHint, idempotentHint, and destructiveHint, but the description goes far beyond that, detailing fallback behavior when GLEIF/OpenFIGI is unavailable, how unresolved identifiers are explicitly listed, and how multiple lookups are cascaded internally. This adds significant context an agent needs to anticipate outcomes and side effects.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness2/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is extremely long and dense, covering every possible detail, source, and edge case. While front-loaded with the purpose and 'Use FIRST' directive, the sheer volume may overwhelm an agent and obscure the essential points. It could be significantly condensed without losing critical guidance.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with only 2 parameters and no output schema, the description exhaustively covers inputs, outputs, edge cases, fallbacks, and source details. Even though the output schema is absent, the description explains what to expect (e.g., 'unresolved' field, source labels). An agent has all necessary information to invoke this tool correctly in any scenario.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema descriptions for 'type' and 'value' are already robust, with examples and specific instructions (e.g., passing entity name only for bonds). The tool description reinforces these semantics with additional nuance, such as the exact pronunciation of issuer names and the risk of trailing security-class words. This goes beyond the schema and clarifies usage precisely.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with multiple query examples and explicitly states the core function: resolve a user-spoken NAME to canonical/official identifiers. It distinguishes itself from sibling tools like compare_entities and entity_profile by focusing on name-to-ID resolution, and further clarifies scope across company and drug types, making its purpose unmistakable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly instructs 'Use FIRST whenever you have a name but need an ID,' which is a clear when-to-use directive. It also explains the cascading lookup behavior that replaces manual lookups. However, it does not explicitly state when not to use this tool (e.g., when an ID is already known), though the context strongly implies it. The absence of named alternatives is a slight gap.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Xero toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation4/5

Most tools have distinct purposes, but there is some overlap (e.g., ai_visibility_check and scan_competitor_ai_presence are related; memory tools remember/recall/forget form a clear subgroup). Descriptions are detailed enough to differentiate, but the broad scope may cause occasional mis-selection.

Naming Consistency2/5

Naming is inconsistent: some tools use verb_noun (list_accounts, get_profit_and_loss), others are single words (forget, recall), and some use snake_case with mixed verbs (ai_visibility_check, ask_pipeworx, bet_research). No uniform pattern makes the set harder to navigate.

Tool Count3/5

25 tools is high but not extreme given the broad scope (accounting, betting, data queries, npm, memory, etc.). However, the server tries to cover too many domains, making it feel bloated. Each tool is individually useful, but the count is borderline excessive for coherence.

Completeness2/5

The Xero accounting subset is incomplete: only list and get operations, no create/update/delete for invoices, contacts, or accounts. Other domains (betting, npm) are covered well, but the core accounting purpose has significant gaps that will hinder agents.

Resources